Calidi Biotherapeutics (CLDI) Other Accumulated Expenses (2024)
Calidi Biotherapeutics (CLDI) posted quarterly Other Accumulated Expenses of $638000.0 for Q4 2024, up 2.9% quarter-over-quarter from $620000.0 in Q3 2024.
Calidi Biotherapeutics (CLDI) Other Accumulated Expenses (2024) Analysis & Trends
Calidi Biotherapeutics' Other Accumulated Expenses history runs 1 years deep, the most recent figure standing at $638000.0 for Q4 2024.
- In Q4 2024, Other Accumulated Expenses changed N/A year-over-year to $638000.0; the TTM figure through Dec 2024 stood at $638000.0 (changed N/A YoY), while the FY2024 annual figure was $638000.0, changed N/A from the prior year.
- Other Accumulated Expenses for Q4 2024 stood at $638000.0, up from $620000.0 in the prior quarter.
- The five-year high for Other Accumulated Expenses was $638000.0 in Q4 2024, with the low at $567000.0 in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Calidi Biotherapeutics | 1.88 Mn | -2.22 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 638,000.00 |
| Sep 30, 2024 | 620,000.00 |
| Jun 30, 2024 | 597,000.00 |
| Mar 31, 2024 | 567,000.00 |